These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 23279759)

  • 1. Anticoagulation in patients with dilated cardiomyopathy, low ejection fraction, and sinus rhythm: back to the drawing board.
    Mischie AN; Chioncel V; Droc I; Sinescu C
    Cardiovasc Ther; 2013 Oct; 31(5):298-302. PubMed ID: 23279759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anticoagulant therapy in patients with dilated cardiomyopathy].
    Gensini GF; Rostagno C
    Ann Ital Med Int; 1998; 13(4):227-32. PubMed ID: 10349204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dilated cardiomyopathy and role of antithrombotic therapy.
    Abdo AS; Kemp R; Barham J; Geraci SA
    Am J Med Sci; 2010 Jun; 339(6):557-60. PubMed ID: 20186041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotics in heart failure with reduced ejection fraction and normal sinus rhythm: an evidence appraisal.
    Prom R; Usedom JE; Dull RB
    Ann Pharmacother; 2014 Feb; 48(2):226-37. PubMed ID: 24259641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of new drugs for management of atrial fibrillation.
    Hollands JM; Gowan M; Riney JN; Deal EN; Kates AM
    Ann Pharmacother; 2012 Dec; 46(12):1656-70. PubMed ID: 23249869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis.
    Lip GY; Ponikowski P; Andreotti F; Anker SD; Filippatos G; Homma S; Morais J; Pullicino P; Rasmussen LH; Marin F; Lane DA;
    Eur J Heart Fail; 2012 Jul; 14(7):681-95. PubMed ID: 22611046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and predictors of in-hospital mortality of patients with heart failure with preserved left ventricular ejection fraction.
    Pérez de Isla L; Zamorano J; Hernández N; Contreras L; Rodrigo JL; Almería C; Aubele AL; Mataix L; Macaya C
    J Cardiovasc Med (Hagerstown); 2008 Oct; 9(10):1011-5. PubMed ID: 18799963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Assiri A; Al-Majzoub O; Kanaan AO; Donovan JL; Silva M
    Clin Ther; 2013 Jul; 35(7):967-984.e2. PubMed ID: 23870607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulation therapy in patients with heart failure due to systolic dysfunction and sinus rhythm: analysis of REDINSCOR registry.
    Avellana P; Segovia J; Ferrero A; Vázquez R; Brugada J; Borrás X; Alonso-Pulpón L; Cinca J
    Rev Esp Cardiol (Engl Ed); 2012 Aug; 65(8):705-12. PubMed ID: 22464104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study.
    Grimm W; Christ M; Bach J; Müller HH; Maisch B
    Circulation; 2003 Dec; 108(23):2883-91. PubMed ID: 14623812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of oral anticoagulants in patients with atrial fibrillation.
    Greenspon AJ
    Postgrad Med; 2012 Nov; 124(6):7-16. PubMed ID: 23322134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oral anticoagulant therapy in dilated cardiomyopathy. Warfarin treatment results in subgroups of patients at risk of embolic complications].
    Ciaccheri M; Castelli G; Nannini M; Santoro G; Troiani V; Dolara A
    G Ital Cardiol; 1995 Jun; 25(6):689-94. PubMed ID: 7649417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results.
    Pengo V; Crippa L; Falanga A; Finazzi G; Marongiu F; Moia M; Palareti G; Poli D; Testa S; Tiraferri E; Tosetto A; Tripodi A; Siragusa S; Manotti C
    J Thromb Haemost; 2012 Oct; 10(10):1979-87. PubMed ID: 22827490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis.
    Lip GY; Piotrponikowski P; Andreotti F; Anker SD; Filippatos G; Homma S; Morais J; Pullicino P; Rasmussen LH; Marín F; Lane DA;
    Thromb Haemost; 2012 Dec; 108(6):1009-22. PubMed ID: 23093044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does anticoagulation benefit patients with congestive heart failure (CHF) who have reduced left ventricular ejection fraction (LVEF) and are in normal sinus rhythm?
    Shah N; DeLeon D; Schwiebert LP; Mold JW
    J Okla State Med Assoc; 2009 Apr; 102(4):126-7. PubMed ID: 19504981
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.